CA2470668C - 5ht4 partial agonist pharmaceutical compositions - Google Patents
5ht4 partial agonist pharmaceutical compositions Download PDFInfo
- Publication number
- CA2470668C CA2470668C CA2470668A CA2470668A CA2470668C CA 2470668 C CA2470668 C CA 2470668C CA 2470668 A CA2470668 A CA 2470668A CA 2470668 A CA2470668 A CA 2470668A CA 2470668 C CA2470668 C CA 2470668C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- tegaserod
- mixture
- weight
- disintegrant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 239000004031 partial agonist Substances 0.000 title description 8
- 229960002876 tegaserod Drugs 0.000 claims abstract description 26
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims abstract description 25
- 239000007884 disintegrant Substances 0.000 claims abstract description 20
- 239000000314 lubricant Substances 0.000 claims abstract description 18
- 150000003839 salts Chemical group 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 23
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 239000003085 diluting agent Substances 0.000 claims description 14
- 229960000913 crospovidone Drugs 0.000 claims description 13
- 238000007907 direct compression Methods 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 13
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 238000005461 lubrication Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 238000009490 roller compaction Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 abstract 1
- 229940049654 glyceryl behenate Drugs 0.000 description 18
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 13
- 229960001375 lactose Drugs 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 9
- DJHHDLMTUOLVHY-UHFFFAOYSA-N 1,2,3,4-tetrachlorodibenzodioxine Chemical compound C1=CC=C2OC3=C(Cl)C(Cl)=C(Cl)C(Cl)=C3OC2=C1 DJHHDLMTUOLVHY-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 229960004354 tegaserod maleate Drugs 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- -1 PrecirolT"" Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 3
- 108091005482 5-HT4 receptors Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920003085 Kollidon® CL Polymers 0.000 description 2
- 206010054048 Postoperative ileus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- CPDDZSSEAVLMRY-FEQFWAPWSA-N tegaserod maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 CPDDZSSEAVLMRY-FEQFWAPWSA-N 0.000 description 2
- IKBKZGMPCYNSLU-UHFFFAOYSA-N 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine Chemical compound C1=C(OC)C=C2C(C=NNC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01403339A EP1321142A1 (en) | 2001-12-21 | 2001-12-21 | Solid pharmaceutical composition for oral administration of Tegaserod |
| EP01403339.3 | 2001-12-21 | ||
| PCT/EP2002/014674 WO2003053432A1 (en) | 2001-12-21 | 2002-12-20 | 5ht4 partial agonist pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2470668A1 CA2470668A1 (en) | 2003-07-03 |
| CA2470668C true CA2470668C (en) | 2011-07-05 |
Family
ID=8183045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2470668A Expired - Fee Related CA2470668C (en) | 2001-12-21 | 2002-12-20 | 5ht4 partial agonist pharmaceutical compositions |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20050106236A1 (enExample) |
| EP (2) | EP1321142A1 (enExample) |
| JP (1) | JP4718776B2 (enExample) |
| KR (1) | KR100980144B1 (enExample) |
| CN (1) | CN100464749C (enExample) |
| AR (1) | AR037937A1 (enExample) |
| AT (1) | ATE320807T1 (enExample) |
| AU (1) | AU2002361198B2 (enExample) |
| BR (1) | BR0215148A (enExample) |
| CA (1) | CA2470668C (enExample) |
| CO (1) | CO5640102A2 (enExample) |
| CY (1) | CY1105559T1 (enExample) |
| DE (1) | DE60210139T2 (enExample) |
| DK (1) | DK1458377T3 (enExample) |
| EC (1) | ECSP105163A (enExample) |
| EG (1) | EG24194A (enExample) |
| ES (1) | ES2258171T3 (enExample) |
| HU (1) | HU226589B1 (enExample) |
| IL (2) | IL162451A0 (enExample) |
| MX (1) | MXPA04006157A (enExample) |
| MY (1) | MY139546A (enExample) |
| NO (1) | NO20042779L (enExample) |
| NZ (1) | NZ533585A (enExample) |
| PE (1) | PE20030872A1 (enExample) |
| PL (1) | PL369509A1 (enExample) |
| PT (1) | PT1458377E (enExample) |
| RU (1) | RU2322978C2 (enExample) |
| SI (1) | SI1458377T1 (enExample) |
| TW (1) | TWI260221B (enExample) |
| WO (1) | WO2003053432A1 (enExample) |
| ZA (1) | ZA200404467B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID28510A (id) * | 1998-08-21 | 2001-05-31 | Novartis Ag | Formulasi oral yang baru untuk agonis atau antagonis 5-ht4 |
| BR122018074353B8 (pt) | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004085393A1 (en) * | 2003-03-25 | 2004-10-07 | Hetero Drugs Limited | Novel crystalline forms of tegaserod maleate |
| US20070065801A1 (en) * | 2003-05-21 | 2007-03-22 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4) |
| PE20050253A1 (es) * | 2003-07-24 | 2005-06-03 | Novartis Ag | Modificaciones estables de maleato de hidrogeno de tegaserod |
| AR045637A1 (es) | 2003-09-12 | 2005-11-02 | Amgen Inc | Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio |
| EP1594493A2 (en) * | 2003-12-16 | 2005-11-16 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of tegaserod base and salts thereof |
| CZ298399B6 (cs) * | 2005-05-02 | 2007-09-19 | Zentiva, A. S. | Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu) |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| RU2015107019A (ru) | 2012-08-21 | 2016-10-10 | Эрделикс Инк. | Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CN105392483B (zh) | 2013-04-12 | 2019-03-15 | 阿德利克斯公司 | 用于抑制磷酸盐转运的nhe3结合化合物和方法 |
| CN104922083B (zh) * | 2015-04-15 | 2017-12-22 | 湖南尔康湘药制药有限公司 | 磺胺嘧啶片及其制备方法 |
| WO2017064538A1 (en) * | 2015-10-16 | 2017-04-20 | Nobel Ilac Sanayii Ve Ticaret A.S. | Pharmaceutical compositions of nilotinib hydrochloride |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0820586A (ja) * | 1994-07-05 | 1996-01-23 | Sanwa Kagaku Kenkyusho Co Ltd | １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途 |
| IL117438A (en) * | 1995-03-16 | 2001-12-23 | Lilly Co Eli | Indazolecarboxamides, their preparation and pharmaceutical compositions containing them |
| JPH09194374A (ja) * | 1995-11-14 | 1997-07-29 | Taisho Pharmaceut Co Ltd | 消化器疾患治療剤 |
| DE69713948D1 (de) * | 1996-04-23 | 2002-08-22 | Janssen Pharmaceutica Nv | Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| ID28510A (id) * | 1998-08-21 | 2001-05-31 | Novartis Ag | Formulasi oral yang baru untuk agonis atau antagonis 5-ht4 |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| AU3574500A (en) * | 1999-03-25 | 2000-10-16 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
| ATE399554T1 (de) * | 1999-08-03 | 2008-07-15 | Lilly Icos Llc | Pharmazeutische zusammensetzung enthaltend tadalafil |
-
2001
- 2001-12-21 EP EP01403339A patent/EP1321142A1/en not_active Withdrawn
-
2002
- 2002-12-17 EG EG2002121358A patent/EG24194A/xx active
- 2002-12-19 TW TW091136675A patent/TWI260221B/zh not_active IP Right Cessation
- 2002-12-19 AR ARP020105024A patent/AR037937A1/es not_active Application Discontinuation
- 2002-12-20 JP JP2003554189A patent/JP4718776B2/ja not_active Expired - Fee Related
- 2002-12-20 IL IL16245102A patent/IL162451A0/xx active IP Right Grant
- 2002-12-20 PT PT02796711T patent/PT1458377E/pt unknown
- 2002-12-20 SI SI200230334T patent/SI1458377T1/sl unknown
- 2002-12-20 MY MYPI20024825A patent/MY139546A/en unknown
- 2002-12-20 EP EP02796711A patent/EP1458377B1/en not_active Expired - Lifetime
- 2002-12-20 CN CNB028255321A patent/CN100464749C/zh not_active Expired - Fee Related
- 2002-12-20 PL PL02369509A patent/PL369509A1/xx not_active Application Discontinuation
- 2002-12-20 MX MXPA04006157A patent/MXPA04006157A/es active IP Right Grant
- 2002-12-20 AT AT02796711T patent/ATE320807T1/de active
- 2002-12-20 HU HU0402492A patent/HU226589B1/hu not_active IP Right Cessation
- 2002-12-20 WO PCT/EP2002/014674 patent/WO2003053432A1/en not_active Ceased
- 2002-12-20 KR KR1020047009594A patent/KR100980144B1/ko not_active Expired - Fee Related
- 2002-12-20 AU AU2002361198A patent/AU2002361198B2/en not_active Ceased
- 2002-12-20 DE DE60210139T patent/DE60210139T2/de not_active Expired - Lifetime
- 2002-12-20 ES ES02796711T patent/ES2258171T3/es not_active Expired - Lifetime
- 2002-12-20 BR BR0215148-0A patent/BR0215148A/pt not_active IP Right Cessation
- 2002-12-20 NZ NZ533585A patent/NZ533585A/en not_active IP Right Cessation
- 2002-12-20 CA CA2470668A patent/CA2470668C/en not_active Expired - Fee Related
- 2002-12-20 US US10/499,721 patent/US20050106236A1/en not_active Abandoned
- 2002-12-20 RU RU2004122631/15A patent/RU2322978C2/ru not_active IP Right Cessation
- 2002-12-20 DK DK02796711T patent/DK1458377T3/da active
-
2003
- 2003-01-06 PE PE2003000004A patent/PE20030872A1/es not_active Application Discontinuation
-
2004
- 2004-06-07 ZA ZA200404467A patent/ZA200404467B/en unknown
- 2004-06-10 IL IL162451A patent/IL162451A/en not_active IP Right Cessation
- 2004-07-01 NO NO20042779A patent/NO20042779L/no not_active Application Discontinuation
- 2004-07-15 CO CO04067463A patent/CO5640102A2/es not_active Application Discontinuation
-
2006
- 2006-05-04 CY CY20061100579T patent/CY1105559T1/el unknown
-
2008
- 2008-10-07 US US12/287,232 patent/US20090104263A1/en not_active Abandoned
-
2010
- 2010-06-16 EC EC2010005163A patent/ECSP105163A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090104263A1 (en) | 5-HT4 partial agonist pharmaceutical compositions | |
| EP1058538B9 (en) | Fast disintegrating tablets | |
| CA2272586C (en) | Rapidly disintegrable pharmaceutical composition | |
| US6599530B2 (en) | Oral compacted composition comprising catechol derivatives | |
| NZ532829A (en) | Film coated solid pharmaceutical compositions comprising sumatriptin for treating pain | |
| EP0266707B1 (en) | Sustained release labetalol tablet | |
| HU200924B (en) | Process for producing pharmaceutical compositions comprising terfenadine | |
| US4940580A (en) | Sustained release labetalol tablets | |
| WO2006000583A2 (en) | Oral sustained release formulation of tedisamil with gastric retention properties | |
| AU2002333235B2 (en) | Pharmaceutical formulation containing an LTB4 antagonist | |
| WO2005092293A1 (en) | Formulations of metformin | |
| US5217965A (en) | Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions | |
| EP1906931B1 (en) | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof | |
| US20030229101A1 (en) | Tablets comprising ciprofloxacin hydrochloride | |
| WO2010100658A2 (en) | Stable olanzapine tablets and the process for its preparation | |
| EP3843702A1 (en) | Immediate release fixed-dose combination of memantine and donepezil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20131220 |